Gliadin as a stimulator of innate responses in celiac disease

Marco Londei, Carolina Ciacci, Ida Ricciardelli, Loredana Vacca, Sonia Quaratino, Luigi Maiuri

Research output: Contribution to journalArticle

Abstract

In celiac disease (CD) we have the prototype of an immune mediated response dominated by the activation of the adaptive immune system and in particular of CD4+ HLA class II restricted T cells. Various seminal studies have established the precise mechanism of how antigen (prolamine) specific activation of CD4+ mucosal T cells occurs. Thus, CD is a condition in which T cells and their activation is the essential hinge in the pathogenic process. These functional studies have provided the explanation for the genetic association between CD and certain HLA alleles (HLA DQ2 and DQ8). These genetic, molecular and functional studies have permitted the clarification of a powerful Th1 dominated pro-inflammatory response that characterises the small intestine of active CD patients. Despite this unassailable set of information and reports there are some intriguing points that have been raised by a series of studies which have indicated that CD is not only defined by an aberrant prolamine-induced activation of the adaptive immune system. New evidence and re-assessments of old studies, point to a more complex pathogenic cascade, which may help to unravel some of the residual obscure points of CD pathogenesis. Here, we outline the current concepts that indicate a direct involvement of the adaptive immune system and we discuss all the evidence supporting a direct activation of the innate immune system by fragments of prolamines, which are not recognized T cell epitopes and how they could influence CD. The gliadin-induced activation of the 'innate' immune system might also have a significant role in the induction and persistence of many CD complications and most definitively for the most aggressive one, namely mucosal T cell lymphomas. We further suggest a novel way to harness the unwanted immune response to toxic prolamine, and thus indicate new potential therapeutic strategies to treat or at least control CD.

Original languageEnglish
Pages (from-to)913-918
Number of pages6
JournalMolecular Immunology
Volume42
Issue number8
DOIs
Publication statusPublished - May 2005

Fingerprint

Gliadin
Celiac Disease
Phenylpropanolamine
Immune System
T-Lymphocytes
T-Lymphocyte Epitopes
T-Cell Lymphoma
Poisons
Small Intestine
Molecular Biology
Alleles
Antigens

Keywords

  • Celiac disease
  • Gluten/gliadin
  • IL-15
  • Innate immunity

ASJC Scopus subject areas

  • Molecular Biology
  • Immunology

Cite this

Londei, M., Ciacci, C., Ricciardelli, I., Vacca, L., Quaratino, S., & Maiuri, L. (2005). Gliadin as a stimulator of innate responses in celiac disease. Molecular Immunology, 42(8), 913-918. https://doi.org/10.1016/j.molimm.2004.12.005

Gliadin as a stimulator of innate responses in celiac disease. / Londei, Marco; Ciacci, Carolina; Ricciardelli, Ida; Vacca, Loredana; Quaratino, Sonia; Maiuri, Luigi.

In: Molecular Immunology, Vol. 42, No. 8, 05.2005, p. 913-918.

Research output: Contribution to journalArticle

Londei, M, Ciacci, C, Ricciardelli, I, Vacca, L, Quaratino, S & Maiuri, L 2005, 'Gliadin as a stimulator of innate responses in celiac disease', Molecular Immunology, vol. 42, no. 8, pp. 913-918. https://doi.org/10.1016/j.molimm.2004.12.005
Londei M, Ciacci C, Ricciardelli I, Vacca L, Quaratino S, Maiuri L. Gliadin as a stimulator of innate responses in celiac disease. Molecular Immunology. 2005 May;42(8):913-918. https://doi.org/10.1016/j.molimm.2004.12.005
Londei, Marco ; Ciacci, Carolina ; Ricciardelli, Ida ; Vacca, Loredana ; Quaratino, Sonia ; Maiuri, Luigi. / Gliadin as a stimulator of innate responses in celiac disease. In: Molecular Immunology. 2005 ; Vol. 42, No. 8. pp. 913-918.
@article{7b12fa605e2a44df97f470665e4c46d2,
title = "Gliadin as a stimulator of innate responses in celiac disease",
abstract = "In celiac disease (CD) we have the prototype of an immune mediated response dominated by the activation of the adaptive immune system and in particular of CD4+ HLA class II restricted T cells. Various seminal studies have established the precise mechanism of how antigen (prolamine) specific activation of CD4+ mucosal T cells occurs. Thus, CD is a condition in which T cells and their activation is the essential hinge in the pathogenic process. These functional studies have provided the explanation for the genetic association between CD and certain HLA alleles (HLA DQ2 and DQ8). These genetic, molecular and functional studies have permitted the clarification of a powerful Th1 dominated pro-inflammatory response that characterises the small intestine of active CD patients. Despite this unassailable set of information and reports there are some intriguing points that have been raised by a series of studies which have indicated that CD is not only defined by an aberrant prolamine-induced activation of the adaptive immune system. New evidence and re-assessments of old studies, point to a more complex pathogenic cascade, which may help to unravel some of the residual obscure points of CD pathogenesis. Here, we outline the current concepts that indicate a direct involvement of the adaptive immune system and we discuss all the evidence supporting a direct activation of the innate immune system by fragments of prolamines, which are not recognized T cell epitopes and how they could influence CD. The gliadin-induced activation of the 'innate' immune system might also have a significant role in the induction and persistence of many CD complications and most definitively for the most aggressive one, namely mucosal T cell lymphomas. We further suggest a novel way to harness the unwanted immune response to toxic prolamine, and thus indicate new potential therapeutic strategies to treat or at least control CD.",
keywords = "Celiac disease, Gluten/gliadin, IL-15, Innate immunity",
author = "Marco Londei and Carolina Ciacci and Ida Ricciardelli and Loredana Vacca and Sonia Quaratino and Luigi Maiuri",
year = "2005",
month = "5",
doi = "10.1016/j.molimm.2004.12.005",
language = "English",
volume = "42",
pages = "913--918",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Gliadin as a stimulator of innate responses in celiac disease

AU - Londei, Marco

AU - Ciacci, Carolina

AU - Ricciardelli, Ida

AU - Vacca, Loredana

AU - Quaratino, Sonia

AU - Maiuri, Luigi

PY - 2005/5

Y1 - 2005/5

N2 - In celiac disease (CD) we have the prototype of an immune mediated response dominated by the activation of the adaptive immune system and in particular of CD4+ HLA class II restricted T cells. Various seminal studies have established the precise mechanism of how antigen (prolamine) specific activation of CD4+ mucosal T cells occurs. Thus, CD is a condition in which T cells and their activation is the essential hinge in the pathogenic process. These functional studies have provided the explanation for the genetic association between CD and certain HLA alleles (HLA DQ2 and DQ8). These genetic, molecular and functional studies have permitted the clarification of a powerful Th1 dominated pro-inflammatory response that characterises the small intestine of active CD patients. Despite this unassailable set of information and reports there are some intriguing points that have been raised by a series of studies which have indicated that CD is not only defined by an aberrant prolamine-induced activation of the adaptive immune system. New evidence and re-assessments of old studies, point to a more complex pathogenic cascade, which may help to unravel some of the residual obscure points of CD pathogenesis. Here, we outline the current concepts that indicate a direct involvement of the adaptive immune system and we discuss all the evidence supporting a direct activation of the innate immune system by fragments of prolamines, which are not recognized T cell epitopes and how they could influence CD. The gliadin-induced activation of the 'innate' immune system might also have a significant role in the induction and persistence of many CD complications and most definitively for the most aggressive one, namely mucosal T cell lymphomas. We further suggest a novel way to harness the unwanted immune response to toxic prolamine, and thus indicate new potential therapeutic strategies to treat or at least control CD.

AB - In celiac disease (CD) we have the prototype of an immune mediated response dominated by the activation of the adaptive immune system and in particular of CD4+ HLA class II restricted T cells. Various seminal studies have established the precise mechanism of how antigen (prolamine) specific activation of CD4+ mucosal T cells occurs. Thus, CD is a condition in which T cells and their activation is the essential hinge in the pathogenic process. These functional studies have provided the explanation for the genetic association between CD and certain HLA alleles (HLA DQ2 and DQ8). These genetic, molecular and functional studies have permitted the clarification of a powerful Th1 dominated pro-inflammatory response that characterises the small intestine of active CD patients. Despite this unassailable set of information and reports there are some intriguing points that have been raised by a series of studies which have indicated that CD is not only defined by an aberrant prolamine-induced activation of the adaptive immune system. New evidence and re-assessments of old studies, point to a more complex pathogenic cascade, which may help to unravel some of the residual obscure points of CD pathogenesis. Here, we outline the current concepts that indicate a direct involvement of the adaptive immune system and we discuss all the evidence supporting a direct activation of the innate immune system by fragments of prolamines, which are not recognized T cell epitopes and how they could influence CD. The gliadin-induced activation of the 'innate' immune system might also have a significant role in the induction and persistence of many CD complications and most definitively for the most aggressive one, namely mucosal T cell lymphomas. We further suggest a novel way to harness the unwanted immune response to toxic prolamine, and thus indicate new potential therapeutic strategies to treat or at least control CD.

KW - Celiac disease

KW - Gluten/gliadin

KW - IL-15

KW - Innate immunity

UR - http://www.scopus.com/inward/record.url?scp=16844372098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844372098&partnerID=8YFLogxK

U2 - 10.1016/j.molimm.2004.12.005

DO - 10.1016/j.molimm.2004.12.005

M3 - Article

C2 - 15829281

AN - SCOPUS:16844372098

VL - 42

SP - 913

EP - 918

JO - Molecular Immunology

JF - Molecular Immunology

SN - 0161-5890

IS - 8

ER -